首页> 美国卫生研究院文献>The Oncologist >Intergroup Randomized Phase III Study of Postoperative Oxaliplatin 5‐Fluorouracil and Leucovorin Versus Oxaliplatin 5‐Fluorouracil Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG‐ACRIN Research Group (E5204)

【2h】

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin 5‐Fluorouracil and Leucovorin Versus Oxaliplatin 5‐Fluorouracil Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG‐ACRIN Research Group (E5204)

机译：术前放化疗的II期或III期直肠癌患者术后奥沙利铂5-氟尿嘧啶和白叶甲素的组间随机III期研究与奥沙利铂5-氟尿嘧啶白叶素和贝伐单抗的比较：ECOG-ACRIN研究小组的一项试验（E5204 ）

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

The addition of bevacizumab to chemotherapy improved outcomes for patients with metastatic colon cancer. E5204 was designed to test whether the addition of bevacizumab to mFOLFOX6, following neoadjuvant chemoradiation and definitive surgery, could improve overall survival (OS) in patients with stage II/III adenocarcinoma of the rectum.

机译：在化疗中加入贝伐单抗可改善转移性结肠癌患者的预后。 E5204旨在测试在新辅助化学放疗和定性手术后在mFOLFOX6中添加贝伐单抗是否可以改善直肠II / III期腺癌患者的总体生存（OS）。

著录项

期刊名称 The Oncologist
作者
A. Bapsi Chakravarthy; Fengmin Zhao; Neal J. Meropol; Patrick J. Flynn; Lynne I. Wagner; Jeffrey Sloan; Robert B. Diasio; Edith P. Mitchell; Paul Catalano; Bruce J. Giantonio; Robert B. Catalano; Daniel G. Haller; Rashid A. Awan; Mary F. Mulcahy; Timothy E. OBrien; Roger Santala; Christine Cripps; John R. Weis; James N. Atkins; Cynthia G. Leichman; Nicholas J. Petrelli; Frank A. Sinicrope; James D. Brierley; Joel E. Tepper; Peter J. ODwyer; Elin R. Sigurdson; Stanley R. Hamilton; David Cella; Al B. Benson; III;
展开▼
作者单位

展开▼
年(卷),期 2020(25),5
年度 2020
页码 -1
总页数 10
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Bevacizumab; Avastin; Adjuvant therapy; Rectal cancer; Antiangiogenesis;

机译：贝伐单抗;阿瓦斯汀;辅助治疗;直肠癌;抗血管生成;

相似文献

外文文献
中文文献

1. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5‐Fluorouracil, and Leucovorin Versus Oxaliplatin, 5‐Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG‐ACRIN Research Group (E5204) [J] . Chakravarthy A. Bapsi, Zhao Fengmin, Meropol Neal J., The oncologist . 2020,第5期

机译：术后Oxaliplatin，5-氟尿嘧啶和白杨蛋白的杂项随机阶段III研究与术前校长阶段II或III直肠癌患者的奥沙利铂，5-氟尿嘧啶，白杨蛋白和贝伐单抗：ECOG-acrin研究组的试验（E5204 的）
2. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204) [J] . A. Bapsi Chakravarthy, Bruce J. Giantonio, Robert B. Catalano, The oncologist . 2020,第5期

机译：术后Oxaliplatin，5-氟尿嘧啶和白杨蛋白的杂项随机阶段III研究与术前校长阶段II或III直肠癌患者的奥沙利铂，5-氟尿嘧啶，白杨蛋白和贝伐单抗：ECOG-acrin研究组的试验（E5204 的）
3. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 [J] . Landry Jerome C., Feng Yang, Prabhu Roshan S., The oncologist . 2015,第6期

机译：局部晚期直肠癌患者术前放开卡培他滨，奥沙利铂和贝伐单抗并发手术及术后5-氟尿嘧啶，白叶素，奥沙利铂（FOLFOX）和贝伐单抗的术前放疗的二期试验：5年临床结果ECOG-ACRIN癌症研究E3204组
4. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil Leucovorin Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 [O] . Jerome C. Landry, Yang Feng, Roshan S. Prabhu, 2015

机译：局部晚期直肠癌患者术前放开卡培他滨奥沙利铂和贝伐单抗联合手术及术后5-氟尿嘧啶白叶素奥沙利铂（FOLFOX）和贝伐单抗的术前放疗的II期试验：5年临床结果ECOG-ACRIN癌症研究E3204组
5. Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5‐Fluorouracil, and Leucovorin Versus Oxaliplatin, 5‐Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG‐ACRIN Research Group (E5204) [O] . A. Bapsi Chakravarthy, Fengmin Zhao, Neal J. Meropol, 2019

机译：术后Oxaliplatin，5-氟尿嘧啶和白杨蛋白的跨组随机化第三阶段研究术前II或III型直肠癌患者的奥沙利铂，5-氟尿嘧啶，白草素和Bevacizumab接受术前化学校长：ECOG-acrin研究组的试验（E5204 ）

Intergroup Randomized Phase III Study of Postoperative Oxaliplatin 5‐Fluorouracil and Leucovorin Versus Oxaliplatin 5‐Fluorouracil Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG‐ACRIN Research Group (E5204)

摘要

著录项

相似文献

相关主题

期刊订阅